Form 4: Travere Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Gary A Lyons, a Director of Travere Therapeutics, Inc., sold 10,000 shares of common stock on August 17, 2026.
Summary
- Option exercise/conversion: acquired 5,000 Common Stock at $17.44 ($87,200) on August 17, 2026; holds 66,500 after (Direct).
- Open-market sale: disposed of 1,900 Common Stock at $62.53 ($118,805) on August 17, 2026; holds 64,600 after (Direct).
- Open-market sale: disposed of 2,600 Common Stock at $63.50 ($165,100) on August 17, 2026; holds 62,000 after (Direct).
- Open-market sale: disposed of 500 Common Stock at $64.16 ($32,081) on August 17, 2026; holds 61,500 after (Direct).
- Option exercise/conversion: acquired 5,000 Common Stock at $17.44 ($87,200) on August 18, 2026; holds 66,500 after (Direct).
- Open-market sale: disposed of 4,100 Common Stock at $63.27 ($259,390) on August 18, 2026; holds 62,400 after (Direct).
- Open-market sale: disposed of 900 Common Stock at $63.86 ($57,470) on August 18, 2026; holds 61,500 after (Direct).
- Option exercise/conversion: disposed of 5,000 Stock option (right to buy) on August 17, 2026; holds 5,000 after (Direct).
- Option exercise/conversion: disposed of 5,000 Stock option (right to buy) on August 18, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $632,846 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Gary A Lyons — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Option exercise/conversion | Common Stock | 5,000 | $17 | $87.2K | 66,500 |
| 2026-08-17 | Open-market sale | Common Stock | 1,900 | $63 | $118.8K | 64,600 |
| 2026-08-17 | Open-market sale | Common Stock | 2,600 | $63 | $165.1K | 62,000 |
| 2026-08-17 | Open-market sale | Common Stock | 500 | $64 | $32.1K | 61,500 |
| 2026-08-18 | Option exercise/conversion | Common Stock | 5,000 | $17 | $87.2K | 66,500 |
| 2026-08-18 | Open-market sale | Common Stock | 4,100 | $63 | $259.4K | 62,400 |
| 2026-08-18 | Open-market sale | Common Stock | 900 | $64 | $57.5K | 61,500 |
| 2026-08-17 | Option exercise/conversion | Stock option (right to buy) | 5,000 | — | — | 5,000 |
| 2026-08-18 | Option exercise/conversion | Stock option (right to buy) | 5,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Option exercise/conversion (5,000 shares) |
| 2026-08-17 | Open-market sale (1,900 shares) |
| 2026-08-17 | Open-market sale (2,600 shares) |
| 2026-08-17 | Open-market sale (500 shares) |
| 2026-08-18 | Option exercise/conversion (5,000 shares) |
| 2026-08-18 | Open-market sale (4,100 shares) |
| 2026-08-18 | Open-market sale (900 shares) |
| 2026-08-17 | Option exercise/conversion (5,000 shares) |
| 2026-08-18 | Option exercise/conversion (5,000 shares) |
Keywords
insider transaction, Form 4, TVTX, Travere Therapeutics, Inc., bearish, Gary A Lyons
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.